A patient has been taking Contrave (naltrexone 8 mg/bupropion 90 mg) for 8 weeks and reports that the appetite‑suppressing effect has diminished; is this expected?

Diminished Appetite Suppression at 8 Weeks on Contrave: Expected Finding

Yes, experiencing a waning appetite-suppressant effect at 8 weeks on Contrave is a recognized phenomenon, though not explicitly labeled as "tolerance" in the literature—this represents an important clinical decision point where you should evaluate whether the patient has achieved at least 5% weight loss to determine if continuation is warranted.

Understanding the Timeline and Response Assessment

The FDA label explicitly states that response to therapy should be evaluated after 12 weeks at the maintenance dosage 1. Your patient at 8 weeks is still within the critical evaluation window. The key question is not whether appetite suppression feels as strong, but whether weight loss is occurring.

Critical Decision Point at Week 12

• If the patient has NOT lost at least 5% of baseline body weight by week 12, discontinue Contrave, as it is unlikely they will achieve clinically meaningful weight loss with continued treatment 1
• This 12-week checkpoint is the evidence-based threshold for determining medication efficacy
• The subjective sensation of appetite suppression may not correlate directly with actual weight loss outcomes

What the Evidence Shows About Contrave's Effects Over Time

The phase III trials (COR-I, COR-II, COR-BMOD, COR-DM) demonstrated that weight loss with naltrexone/bupropion continues progressively through 56 weeks, with mean weight reductions of 5.9% to 11.5% among completers 2. Importantly:

• At 3 months: mean 7.9% total weight loss
• At 6 months: mean 10.3% total weight loss
• At 12 months: mean 11.5% total weight loss 3

This progressive weight loss pattern through nearly a year of treatment argues against true pharmacologic tolerance—if tolerance were occurring, you would expect weight loss to plateau or reverse after the initial weeks.

The Mechanism and Craving Control

Naltrexone/bupropion works through dual mechanisms: bupropion stimulates hypothalamic proopiomelanocortin neurons while naltrexone blocks opioid-mediated autoinhibition, reducing reactivity to food cues and improving dysregulation of eating control in mesolimbic reward pathways 4, 2.

A pooled analysis of 1,967 patients showed that improvements in craving control, positive mood, and specific food cravings (savory foods, high fats, fast-food fats) were sustained through 56 weeks 5. This suggests the medication's effects on the reward system and craving control persist long-term, even if subjective appetite suppression feels different.

Common Clinical Pitfalls

The High-Fat Meal Problem

Contrave should NOT be taken with high-fat meals because this causes a significant increase in bupropion and naltrexone systemic exposure 1. If your patient has been taking it with fatty meals:

• This could cause initial higher drug levels (stronger appetite suppression early on)
• Followed by inconsistent effects as meal composition varies
• Instruct the patient to take with meals, but specifically avoid high-fat meals

Dose Escalation Completion

Verify the patient completed the full dose escalation to 2 tablets twice daily (32 mg naltrexone/360 mg bupropion) by week 4 1. Suboptimal dosing is a common reason for inadequate response.

Side Effect Tolerance vs. Efficacy Tolerance

The real-world data shows that 52.7% of patients discontinued within 12 months, often due to side effects 3. What patients may interpret as "waning effect" could actually be:

• Adaptation to initial side effects (nausea, which affects 23.5% during buildup and is the most common adverse event)
• Reduced awareness of the medication's effects as they become the new baseline
• Psychological adaptation to the medication rather than true pharmacologic tolerance

Practical Management Strategy

1. Measure objective weight loss: Calculate percentage weight loss from baseline. This is the definitive metric, not subjective appetite sensation.

2. Continue through week 12 before making discontinuation decisions, unless intolerable side effects occur 1

3. Reinforce lifestyle modifications: The medication is approved as an adjunct to reduced-calorie diet and increased physical activity 4, 2

4. Monitor for early responders: Patients who achieved 5% weight reduction in the first 3 months of full dosing lost nearly 12% on average by 56 weeks 2

5. Check medication timing: Ensure morning and evening dosing, with meals but not high-fat meals 1

When to Consider Alternatives

If at week 12 the patient has not achieved 5% weight loss, discontinue Contrave and consider alternative anti-obesity medications 1. The 2025 AACE guidelines note that in systematic reviews, phentermine-topiramate was associated with greater weight loss compared to naltrexone-bupropion 4, and GLP-1 receptor agonists (liraglutide, semaglutide) or GIP/GLP-1 agonists (tirzepatide) demonstrate substantially greater weight loss (15-21% with tirzepatide) 4.

The subjective waning of appetite suppression at 8 weeks does not automatically indicate treatment failure—objective weight loss through week 12 is the determining factor for continuation.